Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids

This study has been completed.

Sponsors and Collaborators:	Ospedale Regionale Bellinzona e Valli Brahms SA, D-16761 Hennigsdorf bei Berlin
Information provided by:	Ospedale Regionale Bellinzona e Valli
ClinicalTrials.gov Identifier:	NCT00141973

Purpose

A systemic treatment with corticosteroids has been advocated for various bacterial infectious diseases. Since the production of CRP is down-regulated by corticosteroids, a smaller increase or a more rapid decrease of this acute phase protein will:

suggest attenuated systemic inflammation, but
does not necessarily reflect adequate therapy of the infection.

For several reasons (good diagnostic tool for sepsis, induction not decreased by immunosuppressive therapy), procalcitonin could be a better marker for activity of sepsis in patients under corticosteroids. As this issue has not yet been examined the investigators will prospectively study the time-course of PTC and CRP in a well-defined septic patient group, that in adjunction to antibiotic therapy also received systemic corticosteroid treatment and compare it to a similar group without corticosteroid treatment.

Condition
Sepsis

MedlinePlus related topics: Sepsis

Drug Information available for: Corticosteroids Procalcitonin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Further study details as provided by Ospedale Regionale Bellinzona e Valli:

Study Start Date:	November 2004
Estimated Study Completion Date:	December 2005

Eligibility

Ages Eligible for Study:	50 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Acute exacerbation of chronic obstructive pulmonary disease (COPD) due to bacterial pneumonia

Exclusion Criteria:

Chronic systemic use of corticosteroids

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141973

Locations

Switzerland, Ticino
Ospedale Regionale Bellinzona e Valli
Bellinzona, Ticino, Switzerland, 6500
Ospedale Regionale Bellinzona e Valli
Bellinzona, Ticino, Switzerland, 6500

Sponsors and Collaborators

Ospedale Regionale Bellinzona e Valli

Brahms SA, D-16761 Hennigsdorf bei Berlin

Investigators

Principal Investigator:

Andreas Perren, MD

Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona

More Information

Study ID Numbers:	CE1408
Study First Received:	September 1, 2005
Last Updated:	May 13, 2008
ClinicalTrials.gov Identifier:	NCT00141973
Health Authority:	Switzerland: Swissmedic

Keywords provided by Ospedale Regionale Bellinzona e Valli:

Procalcitonin
Sepsis
Corticosteroids

Study placed in the following topic categories:

Systemic Inflammatory Response Syndrome
Sepsis
Inflammation

Additional relevant MeSH terms:

Pathologic Processes
Infection

ClinicalTrials.gov processed this record on January 13, 2009